Nuclear and mitochondrial targets in tumor cells

Nuclear and mitochondrial targets in tumor cells encompass a diverse array of molecular structures and pathways located within these two vital organelles that are leveraged for oncological intervention. Nuclear targets typically include genomic DNA, histones, and enzymes such as topoisomerases and DNA polymerases, which are essential for maintaining genetic integrity and driving cell proliferation (Source: PubMed, PMID: 25103002). Mitochondrial targets, often referred to as mitocans, involve the electron transport chain, the BCL-2 family of pro-apoptotic and anti-apoptotic proteins, and the mitochondrial permeability transition pore (Source: PubMed, PMID: 23163348). While nuclear-targeted therapies like cisplatin and doxorubicin focus on inducing DNA damage and inhibiting replication, mitochondrial-targeted agents aim to disrupt cellular bioenergetics and directly trigger the intrinsic apoptotic pathway (Source: NIH, National Cancer Institute). This dual-compartment approach is significant because cancer cells often exhibit metabolic shifts, such as the Warburg effect, and genomic instability, making both organelles prime sites for therapeutic attack. However, because these targets are also present in healthy cells, achieving selectivity remains a major challenge in drug development.

Other names

Subcellular oncological targetsNuclear-mitochondrial axisOrganelle-specific cancer targetsDual-compartment tumor targets

Inhibition of DNA replication, induction of DNA damage, disruption of mitochondrial membrane potential, and activation of the intrinsic apoptotic pathway.